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SHORT COMMUNICATION
Cathepsin D assay in ovarian cancer: correlation with pathological
features and receptors for oestrogen, progesterone and epidermal growth
factor
G. Scambia, P. Benedetti, G. Ferrandina, F. Battaglia, G. Baiocchi & S. Mancuso
Department ofGynecology, Catholic University, Rome, Italy.
Summary Using an immunoradiometric assay, Cathepsin-D (Cath-D) concentrations were measured in the
cytosol of 68 normal and neoplastic human ovarian tissues. Cath-D levels were higher in malignant tumours
than in normal tissue samples (P <0.01) and benign tumours (P <0.01). In six out of seven cases, metastatic
deposits showed Cath-D concentrations higher than the respective primary tumours. Using 12 of 17
pmolsmg-' protein as cut-off levels, the Cath-D status (high or low) was not related to any pathological
parameter. Moreover, no correlation was found between Cath-D levels and receptors for oestrogen, pro-
gesterone and epidermal growth factor.
Our results indicate that ovarian tumours produce Cath-D. Further studies are needed to evaluate whether
this protein could represent a prognostic factor for this neoplasia.
Research on proteolytic enzymes has recently provoked con-
siderable interest because they may be involved in the process
of tumour invasion and metastatisation (Goldfarb, 1986).
Among these enzymes much attention has been focused on
Cathepsin D (Cath-D), a lysosomal aspartyl endopeptidase
(Barrett, 1977), which has been found to be identical to the
oestrogen induced 52% glycoprotein first described by West-
ley and Rochefort in MCF-7 cells (Westley & Rochefort,
1979; Morisset et al., 1986). This Cath-D-52 K protein,
secreted by human breast cancer cells, displays a mitogenic
effect in vitro (Vignon et al., 1986) and a proteolytic effect on
extracellular matrix after its autoactivation at acidic pH
(Briozzo et al., 1988). Accordingly, it could have a role in the
control of the growth and spread of human breast cancer.
Moreover, in breast cancer a high cytosolic concentration of
Cath-D is associated with a shorter relapse-free survival
(Thorpe et al., 1989; Spyratos et al., 1989).
At present only few data are available on the presence of
Cath-D in malignancies other than breast cancer (Garcia et
al., 1986; Maudelonde et al., 1990).
In the present study, the concentrations of Cath-D were
assayed by an immunoradiometric method in human ovarian
cancer cytosols and correlated with other pathological and
biological parameters.
al., 1988, 1989). Oestrogen (ER) and progesterone receptors
(PR) were measured by a dextran coated charcoal assay
according to EORTC protocol (1980), using 17-B-oestradiol
(81 Ci mmol-') and 3H-ORG-2058 (57 Ci mmolh') (both
from Amersham International plc) as radiolabelled ligands.
EGF receptors (EGFR) were assayed on the membrane frac-
tion as previously described (Battaglia et al., 1988) using
1251-EGF (Amersham International plc) as radiolabelled
ligand. Cath-D concentration was assayed using a solid phase
two site immunoradiometric assay (CIS Bioindustries, Gift-
sur Yvette, France) in which the first monoclonal antibody
(D7E3) is coated on the ELSA solid phase and the second
one, MIG8, radiolabelled with 1251 is used as a tracer
(Brouillet et al., 1990). For the Cath-D assay, cytosol protein
concentration, measured by the Bradford method (1976)
using bovine serum albumin as the standard, was reset to
about I mg ml-' before the assay. Cytosols were then diluted
1/40 and 1/80 with the diluent contained in the kit. Radio-
activity was measured in a counter for 1 min. Intra- and
inter-assay variations were 6.4% and 8.5% respectively.
Statistical analysis was performed by Student's t-test. Chi-
square test and Fisher's exact test were used to evaluate the
distribution of Cath-D values according to different
variables.
Results
Materials and methods
Fifty-three primary ovarian tumours, seven benign tumours
and eight normal ovaries were studied. Patient age ranged
from 29 to 71 years old (median 53 years). All tissue speci-
mens were frozen on dry ice shortly after surgical removal
and stored at - 80C until processed. Tumours were staged
according to FIGO criteria and histologically graded from
Gl to G3.
Tissue samples were homogenised in ice-cold buffer con-
sisting of 25 mM Tris, 1.5 mM EDTA, 5 mM NaN3, 10mM
monothioglycerol and 20% glycerol. Cytosol and membrane
fractions were prepared as previously described (Battaglia et
Figure 1 shows the distribition of Cath-D values in normal
and neoplastic ovarian specimens. Overall, Cath-D concen-
tration was significantly higher in malignant tumours
(mean ± s.e.m., 15.82 ± 1.06 pmoles mg-' protein) than in
normal tissue samples (7.30 ± 1.42 pmoles mg-' protein)
(P <0.01) and benign tumours (7.10 ± 1.75 pmoles mg-'
protein) (P <0.01). In seven patients, Cath-D was evaluated
in primary tumour and in simultaneous omental metastases.
In all cases but one, higher Cath-D concentrations were
found in metastatic deposits than in primary tumours.
Table I shows the correlation between Cath-D status and
different variables in ovarian cancer. To define Cath-D status
two arbitrary cut-off values of 12 pmoles mg-' protein and
17 pmoles mg-' protein (corresponding approximately to the
mean ± 1 s.d. and the mean ± 2 s.d. of normal samples,
respectively) were adopted. Overall, Cath-D levels were
found to be above 12 or 17 pmoles mg-' protein in 66% and
36% of the cases, respectively. At both cut-off Cath-D status
was not related to any pathological parameter. Moreover, no
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correlation was found between Cath-D levels and ER, PR
and EGFR content.
Discussion
To our knowledge, this is the first report on the assay of
Cath-D in the cytosol of normal and neoplastic ovarian
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Figure 1 Cath-D levels in normal and neoplastic ovarian tissue.
Cath-D concentration was measured as detailed in Materials and
methods.
tissue. Interestingly, Cath-D levels were significantly higher in
ovarian cancer than in normal ovary. Similar findings have
previously been obtained when breast (Garcia et al., 1987)
and endometrial cancer (Maudelonde et al., 1990) specimens
were compared to their normal counterparts. Moreover, the
secretion of Cath-D and other cathepsins is 10-fold greater in
breast cancer cells than in normal mammary cells in culture
(Rochefort et al., 1987).
It is worth noting that scattered Cath-D levels were found
in our ovarian cancer series. Since Cath-D is a proteolytic
enzyme which may be secreted by cancer cells to facilitate
tumour invasion (Briozzo et al., 1988) and may also be an
autocrine mitogen (Vignon et al., 1986), the difference in
Cath-D content might represent a biochemical characteristic
reflecting a different biological aggressiveness. Our finding of
high Cath-D levels in metastatic ovarian tumours support the
hypothesis that Cath-D production may in some way be
linked to tumour progression and invasiveness. In fact, in
human breast cancer Cath-D is a powerful independent prog-
nostic factor in predicting relapse-free survival (Thorpe et al.,
1989; Spyratos et al., 1989). The lack of correlation between
Cath-D levels and other prognostic parameters such as a
stage, histotype, grading and EGF-R (Bauknecht et al., 1988;
Battaglia et al., 1989) could indicate that, like in human
breast cancer, the prognostic value of Cath-D could be
additive (Maudelonde et al., 1988; Brouillet et al., 1990). It
has also to be taken into account, however, that the tumour
concentrations of Cath-D may be influenced by the propor-
tion of stromal and inflammatory components (Imort et al.,
1983). Further immunohistochemical studies should be ad-
dressed to verify this point.
The mechanism of the mitogenic action of Cath-D is
unknown. As for other proteases, Cath-D may act indirectly
by releasing growth factors, such as TGF alpha, from precur-
sors or from extracellular metrix and/or by activating growth
factor receptors (Derynck et al., 1984; Lawrence et al., 1985).
However, the lack ofcorrelation between Cath-D and EGFR
suggests that the tissue binding capacity for EGF is not
influenced by Cath-D content.
It is well known that Cath-D levels are regulated by
oestrogen in human breast cancer cells (Westley & Rochefort,
1979) and by progesterone in rat uterus (Elangovan, 1980)
and human endometrium (Maudelonde et al., 1990). In our
series, no correlation was found between Cath-D levels and
ER and PR expression. This is consistent with previous
Table I Cath-D status according to different variables in ovarian cancer
Patients with Cath-D Patients with Cath-D
> 12pmolmg-' protein > 17pmolmg-' protein
n n (%) n (%)
Total 53 35 (66) 19 (36)
Stage
I 7 6 (86) 3 (43)
II 3 3 (100) 1 (33)
III 35 21 (60) 12 (34)
IV 8 5 (62) 3 (37)
Histological gradinga
GI 6 5 (83) 1 (17)
G2 11 10 (91) 4 (36)
G3 31 17 (55) 14 (45)
Histotype
Serous 38 24 (63) 12 (31)
Mucinous 5 3 (60) 1 (20)
Endometrioid 6 4 (67) 2 (33)
Undifferentiated 4 4 (100) 4 (100)
Receptors
ER + (> 5 fmolmg-') 29 17 (59) 10 (34)
ER- 24 18 (75) 9 (37)
PR+ (>l0fmolmg') 41 28 (68) 16 (39)
PR- 12 7 (58) 3 (25)
EGF-R + (> 1.5 fmol mg') 28 19 (68) 11 (39)
EGFR - 25 16 (64) 8 (32)
aIn five cases the histological grading was not available.184 G. SCAMBIA et al.
findings showing that the concentrations of Cath-D in breast
and endometrial cancer are independent from receptor status
(Maudelonde et al., 1988, 1990), and that Cath-D is also
constitutively produced and secreted in ER- breast cancer
cells (Garcia et al., 1987). In conclusion our data demon-
strate that ovarian tumours contain Cath-D and that this
protein could represent a possible prognostic marker in these
tumours. This needs to be ascertained by prospective clinical
trials which are now under way.
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